Kjelsåsveien 168 B
183 articles with Nordic Nanovector
Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options - March 18, 2019
An individual participant in Nordic Nanovector ASA's previous share option program, not being a primary insider, has exercised a total number of 17,392 options through exercise of a corresponding number of free-standing warrants. 14,374 of the options are exercised at a strike price of NOK 30.00 per share, and 3,018 of the options are exercised at a strike price of NOK 14.24.
Reference is made to the stock exchange notice on 6 March 2019 where Nordic Nanovector ASA announced the final result of the repair offering, in which 69,051 shares, each with a nominal value of NOK 0.20, at a subscription price of NOK 45.00 were allocated.
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
Nordic Nanovector to Attend Cowen Health Care Conference, BioCapital Europe and Stifel Nordic Healthcare Seminar
Nordic Nanovector ASA announces that members of its senior management team will participate and present at the following upcoming investor conferences during March
Reference is made to the stock exchange notice on 20 February 2019 where Nordic Nanovector ASA (the "Company") announced the commencement of a repair offering of up to 777,777 shares with a par value of NOK 0.20 each (the "Offer Shares") at a subscription price of NOK 45.00 per Offer Share (the "Repair Offering").
The former chairman of Nordic Nanovector ASA, Ludvik Sandnes, has resolved to exercise a total number of 27,121 RSUs that were issued to him in 2016 and 2017 after he had elected to receive all of his remuneration in RSUs.
Nordic Nanovector ASA announces its results for the fourth quarter and full year 2018.
Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2018 Results Presentation and Webcast
Nordic Nanovector ASA announces that it will report its fourth quarter and full year 2018 results on Wednesday, 27 February 2019.
Nordic Nanovector ASA announces that an extraordinary general meeting in the company was held at Thon Hotel Vika Atrium, Munkedamsveien 45, Oslo.
The Board of Directors of Nordic Nanovector ASA has on 31 January 2019 decided to grant 259,000 Performance Share Units to employees in accordance with the authorisation granted at the Annual General Meeting held on 30 May 2018.
Nordic Nanovector ASA - Registration of Share Capital Increase in the Norwegian Register of Business Enterprises
Reference is made to the stock exchange announcement regarding the successful completion of the private placement of Nordic Nanovector ASA published on 25 January 2019.
The Board of Directors of Nordic Nanovector ASA call for an extraordinary general meeting to be held at Thon Hotel Vika Atrium, Munkedamsveien 45, Oslo on 18 February 2019 at 15:00 CET.
Reference is made to the announcement by Nordic Nanovector ASA on 25 January 2019 concerning a private placement with gross proceeds in the amount of approximately NOK 222 million and a contemplated repair issue of up to 777,777 new shares with non-tradeable subscription rights to eligible shareholders.
Nordic Nanovector ASA announces the appointment of Dr Mark Wright as Head of Manufacturing.
Nordic Nanovector: Additional Preclinical Studies With CD37-targeting Radioimmunotherapies for B-cell Malignancies Presented at ASH
Nordic Nanovector ASA notes that two new poster presentations from preclinical studies with CD37-targeting radioimmunotherapies were made at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition (1-4 December 2018 in San Diego, CA, USA).
Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH
Overall response rate (ORR) of 61% and complete response (CR) rate of 28% in 74 patients with indolent non-Hodgkin's lymphoma (iNHL)
Nordic Nanovector ASA November 16, 2018: Increased Share Capital Following Exercise of Employee Share Options
A individual participant in Nordic Nanovector ASA's previous share option program, not being a primary insider, has exercised a total number of 300,000 options through exercise of a corresponding number of free-standing warrants. 185,421 of the options are exercised at a strike price of NOK 25 per share, and 114,579 of the options are exercised at a strike price of NOK 14.24 per share.
Nordic Nanovector ASA (OSE: NANO) announces its third quarter 2018 results today.
Nordic Nanovector ASA will announce its third quarter 2018 results on Tuesday, 6 November 2018.
Nordic Nanovector Announces First Patient Dosed in Archer-1 Trial of Betalutin® Plus Rituximab in Follicular Lymphoma
Nordic Nanovector ASA announces that the first patient has been dosed in the Archer-1 trial investigating Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab (RTX) in second-line follicular lymphoma (2L FL).